Literature DB >> 23033278

Palliative treatments for advanced osteosarcoma.

A F Mavrogenis1, G Rossi, E Palmerini, C Errani, E Rimondi, P Ruggieri, P N Soucacos, P J Papagelopoulos.   

Abstract

Advances in diagnostic imaging, interventional radiology, chemotherapy and surgery greatly improved the outcome of patients with osteosarcoma, and made limb salvage possible without compromising survival. In these patients, the prognosis is influenced by the site and resectability of the tumor, prior malignancy, and histological response to preoperative chemotherapy. Unfortunately, the progress has not been as significant in the treatment of advanced osteosarcoma, namely metastatic, recurrent and unresectable tumor. Yet, although advanced and forecasting a dismal prognosis, advanced osteosarcoma is not necessarily untreatable. Aggressive local and medical treatments, including surgical removal of primary and/or metastatic disease are currently available; however, yet, most treatments aim at palliation. Palliative local treatments including isolated limb perfusion, radiation therapy, embolization, chemoembolization, thermal ablation and cryoablation, all have an important role for these patients. The aim of palliative treatments is to achieve a mild response by offering the least discomfort to the patient with the minimum possible complications, and possibly increase of survival.

Entities:  

Mesh:

Year:  2012        PMID: 23033278

Source DB:  PubMed          Journal:  J BUON        ISSN: 1107-0625            Impact factor:   2.533


  6 in total

1.  Palliative embolization for osteosarcoma.

Authors:  Andreas F Mavrogenis; Giuseppe Rossi; Eugenio Rimondi; Teresa Calabrò; Panayiotis J Papagelopoulos; Pietro Ruggieri
Journal:  Eur J Orthop Surg Traumatol       Date:  2013-09-06

Review 2.  Review of Osteosarcoma and Current Management.

Authors:  Ryan A Durfee; Maryam Mohammed; Hue H Luu
Journal:  Rheumatol Ther       Date:  2016-10-19

3.  TIM-3 expression and its association with overall survival in primary osteosarcoma.

Authors:  Feifei Pu; Fengxia Chen; Zhicai Zhang; Xiangcheng Qing; Hui Lin; Lei Zhao; Ping Xia; Zengwu Shao
Journal:  Oncol Lett       Date:  2019-09-12       Impact factor: 2.967

Review 4.  Current Status and Prospects of Clinical Treatment of Osteosarcoma.

Authors:  Zong-Yuan Jiang; Ji-Bin Liu; Xiao-Feng Wang; Yu-Shui Ma; Da Fu
Journal:  Technol Cancer Res Treat       Date:  2022 Jan-Dec

5.  TIM-3 expression in human osteosarcoma: Correlation with the expression of epithelial-mesenchymal transition-specific biomarkers.

Authors:  Yongjun Shang; Zhanyong Li; Hong Li; Haibo Xia; Zhenhua Lin
Journal:  Oncol Lett       Date:  2013-06-18       Impact factor: 2.967

6.  Effects of the myeloid cell nuclear differentiation antigen on the proliferation, apoptosis and migration of osteosarcoma cells.

Authors:  Chengliang Sun; Chuanju Liu; Jun Dong; Dong Li; Wei Li
Journal:  Oncol Lett       Date:  2014-01-17       Impact factor: 2.967

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.